Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial

BACKGROUND: Cardiomyopathy is a leading cause of death in patients with Duchenne muscular dystrophy and myocardial damage precedes decline in left ventricular systolic function. We tested the efficacy of eplerenone on top of background therapy in patients with Duchenne muscular dystrophy with early...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Neurol
Main Authors: Raman, Subha V, Hor, Kan N, Mazur, Wojciech, Halnon, Nancy J, Kissel, John T, He, Xin, Tran, Tam, Smart, Suzanne, McCarthy, Beth, Taylor, Michael D, Jefferies, John L, Rafael-Fortney, Jill A, Lowe, Jeovanna, Roble, Sharon L, Cripe, Linda H
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4361281/
https://ncbi.nlm.nih.gov/pubmed/25554404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1474-4422(14)70318-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados